On August 11, 2023, Swayampakula Ramakanth, an analyst at HC Wainwright & Co., has reaffirmed a positive outlook on Vor Biopharma (NASDAQ:VOR), giving it a Buy rating and a price target of $17.5. Ramakanth’s assessment is based on a comprehensive evaluation of the company’s performance and future potential. Notably, the average 12-month stock price forecast for Vor Biopharma as of June 12, 2023, stands at $17.06, indicating a substantial projected increase of 445.05%. This optimistic sentiment is further supported by a consensus rating of Buy from a panel of seven analysts.
https://beststocks.com/analyst-reaffirms-positive-outlook-on-vor-bio/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.